

SC-4/15: Listing of lindane

The Conference of the Parties,

Having considered the risk profile and risk management evaluation for lindane transmitted by the Persistent Organic Pollutants Review Committee,¹

Taking note of the recommendation by the Persistent Organic Pollutants Review Committee to list lindane in Annex A of the Convention,²

1. *Decides* to amend part I of Annex A of the Convention to list lindane therein with a specific exemption for the use of lindane as a human health pharmaceutical for the control of head lice and scabies as second line treatment by inserting the following row:

Chemical	Activity	Specific exemption
Lindane* CAS No: 58-89-9	Production	None
	Use	Human health pharmaceutical for control of head lice and scabies as second line treatment

2. *Requests* the Secretariat to cooperate with the World Health Organization in developing reporting and reviewing requirements for the use of lindane as a human health pharmaceutical for the control of head lice and scabies, taking into consideration the concluding statement in the Persistent Organic Pollutants Review Committee's risk management evaluation on lindane, and to report on that cooperation to the Conference of the Parties at its fifth meeting.

1 UNEP/POPS/POPRC.2/17/Add.4 and UNEP/POPS/POPRC.3/20/Add.4.

2 UNEP/POPS/COP.4/17.